September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Addressing the State of Community Oncology in Florida and the Role of FLASCO
June 11th 2019Eric Harris, DO, hematologist/oncologist, Florida Cancer Specialists & Research Institute, gives Targeted Oncology an insiders perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.
Watch
Brigatinib Shows Activity Following Other ALK TKIs in ALK+ NSCLC
June 6th 2019Preliminary results from a phase II trial demonstrated promising activity for brigatinib in patients with non–small cell lung cancer with an <em>ALK </em>rearrangement who have progressed on treatment with another next-generation ALK tyrosine kinase inhibitor.
Read More
Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC
June 6th 2019Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non–small cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.
Watch
Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLC
June 4th 2019Two targeted therapies in development have demonstrated encouraging activity as potential treatments targeting hard-to-target driver alterations in lung cancer. During the 2019 ASCO Annual Meeting, Christine M. Lovly, MD, PhD, reviewed the early promising findings for TAK-788 for patients with non–small cell lung cancer harboring <em>EGFR</em> exon 20 insertions and for BLU-667 for patients with <em>RET </em>rearrangements.
Read More
Frontline Ramucirumab Combo Delays Progression in EGFR+ NSCLC
June 4th 2019When the targeted agents ramucirumab and erlotinib were combined, progression was delayed by 7 months in patients with newly diagnosed <em>EGFR</em>-positive non–small cell lung cancer compared to erlotinib alone, according to findings from the phase III RELAY trial.
Read More
Two MET Inhibitors Demonstrate Clinical Activity in METex14+ NSCLC
June 4th 2019Promising responses have been seen with 2 highly selective, investigational MET inhibitors—tepotinib and capmatinib—in both the first- and second-line setting for patients with <em>MET</em> exon 14–altered advanced non–small cell lung cancer.
Read More
Addition of Atezolizumab Improves PFS in NSCLC With Liver Mets
June 4th 2019According to a subgroup analysis from the phase III IMpower150 trial presented at the 2019 ASCO Annual Meeting, the addition of immunotherapy to bevacizumab and a chemotherapy doublet improved progression-free survival in patients with non–small cell lung cancer and baseline liver metastases.
Read More
Findings From Two Studies Show Positive Results From Neoadjuvant Immunotherapy in NSCLC
June 3rd 2019Findings from 2 studies of patients with operable early-stage non–small cell lung cancer showed preoperative immunotherapy had positive activity and favorable toxicity, according to a presentation at the 2019 ASCO Annual Meeting, and phase III clinical trials are already testing these stratgies.
Read More
Eligibility for Clinical Trial Participation in NSCLC Could Double
June 3rd 2019Nearly double the number of patients with advanced non-small cell lung cancer would be eligibile for clinical trial enrollment if a broader set of eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research was implemented, according to data presented at the 2019 ASCO Annual Meeting.
Read More
Lurbinectedin Monotherapy Demonstrates Promising Responses in Second-Line SCLC
June 2nd 2019Single-agent lurbinectedin induced an overall response rate of 35.2% in the second-line setting for the treatment of patients with small cell lung cancer in a phase II basket trial, presented at the 2019 ASCO Annual Meeting.
Read More
New Approaches Target Overcoming Resistance to TKIs in EGFR+ NSCLC
June 2nd 2019The treatment of <em>EGFR</em>-mutant non–small cell lung cancer has experienced significant improvements with the development of tyrosine kinase inhibitors, but resistance mechanisms that promote disease recurrence have tampered the runaway success of these revolutionary agents, said Katerina A. Politi, PhD, during the 2019 ASCO Annual Meeting. Early findings are presented for 2 novel agents aiming to potentially overcome resistance.
Read More
Updated Results from KEYNOTE-001 Show Favorable 5-Year OS Rates in Advanced NSCLC
June 1st 2019Overall survival from the KEYNOTE-001 trial in patients with advanced non–small cell lung cancer showed treatment with pembrolizumab monotherapy produced more favorable rates of response at 5 years when compared with historical, pre-immunotherapy standard-of-care regimens.
Read More
Oncology Experts Select Top Abstracts Ahead of 2019 ASCO Annual Meeting
May 29th 2019In an interview with <em>Targeted Oncology</em>, experts in gynecology, gastrointestinal, genitourinary, lung, and breast cancers spoke to the significance of the abstracts they are most looking forward to at the 2019 ASCO Annual Meeting.
Read More
NovoTTF-100L Plus Chemotherapy Approved by FDA for Malignant Pleural Mesothelioma
May 24th 2019The NovoTTF-100L System has received approval from the FDA in combination with pemetrexed and platinum-based chemotherapy as a frontline treatment for patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.
Read More
Socinski Details Immunotherapy Trials for the Treatment of Advanced Nonsquamous NSCLC
May 22nd 2019Mark Socinski, MD, explained to a group of physicians at a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation the treatment considerations and decisions he makes when seeing patients with non–small cell lung cancer in the clinic.
Read More
Paik Explains the Rationale for the Second-Line Standard for Patients With Squamous NSCLC
May 17th 2019During a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation, Paul K. Paik, MD, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with non–small cell lung cancer.
Read More
Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC
May 16th 2019Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with <em>EGFR</em>-positive advanced non–small cell lung cancer with leptomeningeal metastases.
Watch
Afatinib Demonstrates Manageable Toxicity, Promising Efficacy in TKI-Naive Patients With EGFR+ NSCLC
May 16th 2019According to results from a phase IIIb interim analysis, afatinib demonstrated a predictable and manageable toxicity profile and promising efficacy in patients with <em>EGFR</em> mutation-positive non–small cell lung cancer.
Read More
Lower Osimertinib Dose Shows Similar Efficacy in EGFR+ NSCLC With Leptomeningeal Metastases
May 15th 2019Myung-Ju Ahn, MD, discusses the results from the AURA LM trial and the next steps that need to be taken in order to confirm the efficacy that was seen with the lower dose. In addition, she highlights where research in the treatment landscape of advanced NSCLC is headed.
Read More
Patients With EGFR+ NSCLC See OS Improvement With Atezolizumab After TKI Failure
May 10th 2019According to findings from an exploratory analysis from the phase III IMpower150 trial presented at the 2019 European Lung Cancer Congress, atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with <em>EGFR</em>-positive metastatic nonsquamous non–small cell lung cancer who have failed on TKI treatment.
Read More
Expert Highlights Ongoing Trial Evaluating Durvalumab Efficacy, Safety in Real-World Setting
May 9th 2019Nicolas Girard, MD, discussed the importance of evaluating durvalumab in a real-world setting. In addition, he highlights other questions that remain unanswered in this area, as well as the role of immunotherapy in patients with NSCLC.
Read More
Significantly higher response rates were seen in patients with <em>ALK</em>-positive non–small cell lung cancer who had been treated with at least 1 prior ALK tyrosine kinase inhibitor before receiving lorlatinib and who harbored an <em>ALK </em>resistance mutation compared with those who did not have an <em>ALK </em>mutation.
Read More
Feliciano Determines Which Patients Are Best Served by Either Immunotherapy or Targeted Therapy
April 25th 2019During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Josephine Louella Feliciano, MD, explained the treatment considerations and decisions she makes when treating a patient with non–small cell lung cancer in the clinic and the data that support these options to a group of physicians.
Read More
PD-L1 IHC 22C3 pharmDX Assay Approval Expanded by FDA in NSCLC
April 19th 2019The approval of the PD-L1 22C3 pharmDX assay has been expanded by the FDA to be used as a companion diagnostic for identifying more patients with stage III or metastatic non–small cell lung cancer who can undergo frontline treatment with pembrolizumab.
Read More
TMB Shows Promise as Biomarker for Durvalumab Activity in NSCLC
April 19th 2019According to new findings, tumor mutational burden showed promise as a predictive biomarker for survival benefit in patients with advanced non–small cell lung cancer (NSCLC) treated with the PD-L1 inhibitor durvalumab (Imfinzi) as initial therapy versus chemotherapy, even though there was no difference seen between the 2 treatment groups in the primary analysis of the randomized trial.
Read More
Levy Works Through Therapy Options in Patients With NSCLC Who Lack a Driver Mutation
April 18th 2019Benjamin P. Levy, MD, recently discussed the treatment considerations and decisions he makes when treating patients with non–small cell lung cancer. Levy, the clinical director of medical oncology and associate professor of oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, revealed his treatment decisions to the group based on 2 case scenarios of patients with NSCLC that does not have a genetic driver.
Read More